NeoGenomics, Inc. (NEO) Guidance & Earnings Results

On 2026-10-05 NeoGenomics, Inc. raised guidance: "Full year total revenue guidance expected to increase at midpoint resulting from third quarter…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NEONeoGenomics, Inc.Follow NEO — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 2.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Oct 26	Raised	Full year total revenue guidance expected to increase at midpoint resulting from third quarter performance · full year
28 Jul 26	Raised	FY2026 revenue raised to $802-806M from $797-803M; adjusted EBITDA raised to $56-58M from $55-57M; net loss improved to $(42)-$(34)M from $(63)-$(50)M · full year
28 Apr 26	Raised	Revenue guidance raised from $793-801M to $797-803M · full year
17 Feb 26	Raised	FY2026 revenue $793-801M (9-10% YoY), adjusted EBITDA $55-57M (27-31% YoY), net loss $(63)-$(50)M.
28 Oct 25	Reaffirmed	FY2025 revenue $720-726M; net loss $(116)-$(108)M; adjusted EBITDA $41-44M · full year
29 Jul 25	Lowered	FY 2025 revenue lowered to $720-726M from $747-759M; net loss widened to $(116)-$(108)M from $(85)-$(77)M; adjusted EBITDA lowered to $41-44M from $55-58M. · full year

NeoGenomics, Inc. — questions

What guidance did NeoGenomics, Inc. give?: On 2026-10-05: "Full year total revenue guidance expected to increase at midpoint resulting from third quarter performance"
When does NeoGenomics, Inc. report earnings?: NeoGenomics, Inc.'s next earnings report is expected on 2026-10-28.

Every figure on this page comes from NeoGenomics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.